Advisornet Financial’s Sarepta Therapeutics SRPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-1
Closed -$22 – 2362
2025
Q4
$22 Sell
1
-3
-75% -$63 ﹤0.01% 2217
2025
Q3
$77 Buy
4
+1
+33% +$18 ﹤0.01% 2199
2025
Q2
$51 Sell
3
-3
-50% -$128 ﹤0.01% 2198
2025
Q1
$383 Buy
6
+1
+20% +$105 ﹤0.01% 2009
2024
Q4
$608 Sell
5
-3
-38% -$368 ﹤0.01% 1737
2024
Q3
$999 Buy
8
+3
+60% +$415 ﹤0.01% 1943
2024
Q2
$790 Hold
5
– – ﹤0.01% 1865
2024
Q1
$647 Sell
5
-1
-17% -$122 ﹤0.01% 1855
2023
Q4
$579 Buy
6
+4
+200% +$384 ﹤0.01% 2059
2023
Q3
$242 Buy
2
+1
+100% +$113 ﹤0.01% 2114
2023
Q2
$115 Sell
1
-1
-50% -$129 ﹤0.01% 2261
2023
Q1
$276 Buy
2
+1
+100% +$130 ﹤0.01% 2199
2022
Q4
$130 Buy
+1
New +$116 ﹤0.01% 2264
2020
Q1
– Sell
-100
Closed -$13K – 1924
2019
Q4
$13K Buy
+100
New +$10.1K ﹤0.01% 1321

Other funds holding SRPT

Advisornet Financial's SRPT Position: Q1 2026 in Review

Advisornet Financial sold out of Sarepta Therapeutics (SRPT) in Q1 2026, closing a stake of 1 share — an estimated $22 sold.

Advisornet Financial first reported a position in SRPT in Q4 2019 and held it in 14 quarters. The position peaked at $13K in Q4 2019. 345 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Advisornet Financial reported no remaining Sarepta Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Advisornet Financial sold 1 Sarepta Therapeutics share in Q1 2026, an estimated $22.
  • Advisornet Financial first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 14 quarters.
  • Advisornet Financial's Sarepta Therapeutics position peaked at $13K in Q4 2019.
  • 345 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Advisornet Financial's 13F filing for Q1 2026, filed 17 Apr 2026.